Cambridge Cognition (LON:COG) had its price objective reduced by investment analysts at FinnCap from GBX 180 ($2.44) to GBX 155 ($2.10) in a research report issued to clients and investors on Wednesday. The brokerage currently has a “corporate” rating on the stock. FinnCap’s price objective would indicate a potential upside of 16.54% from the stock’s previous close.

Cambridge Cognition (LON COG) opened at GBX 133 ($1.80) on Wednesday. Cambridge Cognition has a 1-year low of GBX 68.20 ($0.92) and a 1-year high of GBX 169 ($2.29).

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at

About Cambridge Cognition

Cambridge Cognition Holdings plc and its subsidiaries develop and commercialize computerized neuropsychological tests for sale, principally in the United Kingdom, the United States and Europe. The Company’s segments include Pharmaceutical Clinical Trials, Academic Research and Healthcare Technology. The Pharmaceutical Clinical Trials segment includes products and services for use in regulated pharmaceutical clinical trials.

Receive News & Ratings for Cambridge Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambridge Cognition and related companies with's FREE daily email newsletter.